# NINTEDANIB
> **ANDA212555** · Abbreviated New Drug Application (Generic) · Sponsor: GLENMARK PHARMS LTD · Approved 2026-03-26
## Drug
- **FDA Application Number:** ANDA212555
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** NINTEDANIB
- **Generic name:** Nintedanib Esylate
- **Active ingredients:** NINTEDANIB ESYLATE
- **Dosage form:** CAPSULE
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** GLENMARK PHARMS LTD
- **First approval:** 2026-03-26
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212555)
---
*AI Analytics · CC0 1.0*